Common use of About Gilead Sciences Clause in Contracts

About Gilead Sciences. Gilead Sciences, Inc., headquartered in Foster City, CA, is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. Gilead discovers, develops, manufactures and commercializes proprietary therapeutics for challenging infectious diseases (viral, fungal and bacterial infections) and cancer. Gilead maintains research, development or manufacturing facilities in the United States, Europe and Australia. For more information on Gilead Sciences, please visit the company’s Web site at w▇▇.▇▇▇▇▇▇.▇▇▇ or call the Gilead Corporate Communications Department at 1-800-GILEAD-5 (1-▇▇▇-▇▇▇-▇▇▇▇). Portions of this Exhibit were omitted and have been filed separatelyly with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. University of Colorado [***]1[***]2[***]3[***]4[***]5[***]6[***]7[***]8[***]9[***]10[***]11[***]12[***]13[***]14 Becton, D▇▇▇▇▇▇▇▇ & Company [***]1[***]2[***]3[***]4[***]5 [***] [***]1[***]2[***]3[***]4[***]5[***]6 [***] [***]1[***]2[***]3[***]4[***]5[***]6 Roche Molecular Systems [***]1[***]2[***]3[***]4 [***] [***]1[***]2[***]3[***]4[***]5 [***] [***] [***] [***] [***] [***]1[***]2[***] 3 Portions of this Exhibit were omitted and have been filed separatelyly with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. [***] [***] [***] [***] [***] [***] [***] [***] SELEX ARTICLES 1 (Contains one each of the articles from 1990 through 1996, listed on the file, “SELEX Articles 1990-2001” found on the SELEX Package CDROM.) SELEX ARTICLES 2 (Contains one each of the articles from 1997 through 2001, including the draft articles, listed on the file, “SELEX Articles 1990-2001” found on the SELEX Package CDROM.) [***] [***] [***] [***] US Patent No. [***] [***] [***] US Patent No. [***] (dated August 11, 1998) US Patent No. [***] (dated November 14, 1995) US Patent No. [***] (dated November 11, 1997) US Patent No. [***] (dated February 8, 2000) [***] US Patent No. [***] is available on the Patents Referenced in Misc. [***] CDROM ICT [***] [***] [***] [***] [***] [***] [***] [***] [***] US Patents [***] and [***] are available on the Patents Referenced in Misc. [***] CDROM [***] US Patents [***] and [***] are available on the Patents Referenced in Misc. [***] CDROM [***] [***] Portions of this Exhibit were omitted and have been filed separatelyly with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] European Patent [***] in both German and English (Application dated September 14, 1993) [***] [***] is available on the Patents Referenced in Misc. [***] CDROM [***] [***] [***] Third New Divisional Application [***] [***] [***] [***] [***] [***] Audit Letters Portions of this Exhibit were omitted and have been filed separatelyly with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. January 22, 2001 March 27, 2000 January 26, 2000 March 9, 1999 January 19, 1999 February 18, 1998 October 2, 1997 September 12, 1997 July 28, 1997 July 17, 1997 February 19, 1997 February 9, 1996 February 8, 1996 January 26, 1996

About Gilead Sciences. Gilead Sciences, Inc., headquartered in Foster City, CA, is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. Gilead discovers, develops, manufactures and commercializes proprietary therapeutics for challenging infectious diseases (viral, fungal and bacterial infections) and cancer. Gilead maintains research, development or manufacturing facilities in the United States, Europe and Australia. For more information on Gilead Sciences, please visit the company’s Web site at w▇▇▇.▇▇▇▇▇▇.▇▇▇ or call the Gilead Corporate Communications Department at 1-800-GILEAD-5 (1-▇-▇▇▇-▇▇▇-▇▇▇▇). Portions of this Exhibit were omitted and have been filed separatelyly separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. University of Colorado [***]1[***]2[***]3[***]4[***]5[***]6[***]7[***]8[***]9[***]10[***]11[***]12[***]13[***]14 Becton, D▇▇▇▇▇▇▇▇▇ & Company [***]1[***]2[***]3[***]4[***]5 [***] [***]1[***]2[***]3[***]4[***]5[***]6 [***] [***]1[***]2[***]3[***]4[***]5[***]6 Roche Molecular Systems [***]1[***]2[***]3[***]4 [***] [***]1[***]2[***]3[***]4[***]5 [***] [***] [***] [***] [***] [***]1[***]2[***] 3 Portions of this Exhibit were omitted and have been filed separatelyly separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. [***] [***] [***] [***] [***] [***] [***] [***] SELEX ARTICLES 1 (Contains one each of the articles from 1990 through 1996, listed on the file, “SELEX Articles 1990-2001” found on the SELEX Package CDROM.) SELEX ARTICLES 2 (Contains one each of the articles from 1997 through 2001, including the draft articles, listed on the file, “SELEX Articles 1990-2001” found on the SELEX Package CDROM.) [***] [***] [***] [***] US Patent No. [***] [***] [***] US Patent No. [***] (dated August 11, 1998) US Patent No. [***] (dated November 14, 1995) US Patent No. [***] (dated November 11, 1997) US Patent No. [***] (dated February 8, 2000) [***] US Patent No. [***] is available on the Patents Referenced in Misc. [***] CDROM ICT [***] [***] [***] [***] [***] [***] [***] [***] [***] US Patents [***] and [***] are available on the Patents Referenced in Misc. [***] CDROM [***] US Patents [***] and [***] are available on the Patents Referenced in Misc. [***] CDROM [***] [***] Portions of this Exhibit were omitted and have been filed separatelyly separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] European Patent [***] in both German and English (Application dated September 14, 1993) [***] [***] is available on the Patents Referenced in Misc. [***] CDROM [***] [***] [***] Third New Divisional Application [***] [***] [***] [***] [***] [***] Audit Letters Portions of this Exhibit were omitted and have been filed separatelyly separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. January 22, 2001 March 27, 2000 January 26, 2000 March 9, 1999 January 19, 1999 February 18, 1998 October 2, 1997 September 12, 1997 July 28, 1997 July 17, 1997 February 19, 1997 February 9, 1996 February 8, 1996 January 26, 1996